Vigil Neuroscience, Inc. (VIGL)

Market Cap	123.73M
Revenue (ttm)	n/a
Net Income (ttm)	-82.60M
Shares Out	40.83M
EPS (ttm)	-2.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	759,290
Open	2.930
Previous Close	2.890
Day's Range	2.900 - 3.160
52-Week Range	1.490 - 6.060
Beta	1.85
Analysts	Strong Buy
Price Target	21.00 (+593.07%)
Earnings Date	Mar 25, 2025

About VIGL

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 7, 2022
• Employees: 69
• Stock Exchange: NASDAQ
• Ticker Symbol: VIGL
• Website: https://www.vigilneuro.com

Analyst Forecast

According to 5 analysts, the average rating for VIGL stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 593.07% from the latest price.

Price Target

$21.0

(593.07% upside)

Analyst Consensus: Strong Buy